Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gastrointestinal epithelial glycocalyx is a complex, carbohydrate-rich layer that coats the apical surface of enterocytes, serving as the primary interface between the intestinal mucosa and the luminal environment (Wikipedia, 2024). It is composed of a dense network of transmembrane mucins (such as MUC1, MUC3, and MUC17), proteoglycans (including syndecans and glypicans), and glycosaminoglycans (such as heparan sulfate and hyaluronic acid), which collectively impart a strong anionic charge to the cell surface (NIH, 2019). This structure functions as a critical physical and chemical barrier, protecting the underlying epithelium from mechanical stress, digestive enzymes, and pathogens while selectively regulating the absorption of nutrients and ions (World Journal of Gastroenterology, 2023). Beyond its protective role, the glycocalyx acts as a scaffold for the commensal microbiota and a platform for mechanotransduction and innate immune signaling (NIH, 2024). Degradation or thinning of the glycocalyx is a hallmark of several gastrointestinal disorders, including inflammatory bowel disease (IBD), ulcerative colitis, and gastrointestinal acute radiation syndrome (GI-ARS), leading to increased intestinal permeability and "leaky gut" symptoms (Synedgen, 2024). Therapeutic strategies, such as Synedgen's MIIST platform (e.g., MIIST305), aim to repair and restore the structural integrity and anionic charge of the glycocalyx to enhance mucosal barrier function and resolve inflammation (Synedgen, 2024). Additionally, the glycocalyx presents a significant challenge for the delivery of oral drugs and gene therapies, as its negative charge and mesh-like structure can repel or entrap therapeutic molecules (World Journal of Gastroenterology, 2023).
Restoration of glycocalyx structural integrity and anionic charge to enhance mucosal barrier function, competitively inhibit pathogen adhesion, and modulate innate immune signaling.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gastrointestinal epithelial glycocalyx (FBBG).